IDEAYA Biosciences (IDYA)
About
Business overview of IDEAYA Biosciences (IDYA)
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.
Key Insights
Critical company metrics and information
Share Price
$24.85Market Cap
$2.15 BillionTotal Outstanding Shares
86.43 Million SharesTotal Employees
124Dividend
No dividendIPO Date
May 23, 2019SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQType
Common StockPhone Number
650-443-6209Address
5000 shoreline ct, suite 300, South san francisco, CA, 94080Homepage
https://www.ideayabio.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $248.62 Million |
| Net Cash Flow From Operating Activities | $-149.68 Million |
| Net Cash Flow From Operating Activities, Continuing | $-149.68 Million |
| Net Cash Flow From Investing Activities, Continuing | $-417.39 Million |
| Net Cash Flow, Continuing | $248.62 Million |
| Net Cash Flow From Investing Activities | $-417.39 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Basic Average Shares | $241.86 Million |
| Income Tax Expense/Benefit | $0.00 |
| Diluted Average Shares | $241.86 Million |
| Operating Income/Loss | $-224.75 Million |
| Research and Development | $193.26 Million |
| Revenues | $3.92 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Current Liabilities | $40.66 Million |
| Noncurrent Liabilities | $18.80 Million |
| Noncurrent Assets | $307.66 Million |
| Accounts Receivable | $20,000.00 |
| Equity Attributable To Parent | $1.18 Billion |
| Assets | $1.24 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2025 Financhle. All Rights Reserved.